MTNB Matinas BioPharma Holdings, Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 1582554 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY58.9%
TTM EPS YoY114.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-147.5%
ROA-98.4%
ROIC (approx.)-535.3%
Asset turnover—
Leverage & solvency
Liabilities / assets33.1%
Debt / equity0.00x
Current ratio1.78x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.95x
Accruals ratio-5.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | — | — | — | $0 | $0 | $0 | $85,000 | $2.38M |
| SG&A expense | $1.74M | $1.55M | $1.94M | $1.60M | $1.58M | $1.84M | $1.86M | $1.66M |
| Operating income | -$1.74M | -$1.55M | -$1.94M | -$1.60M | -$1.58M | -$1.84M | -$1.95M | -$8.47M |
| Net income | -$1.76M | -$1.33M | -$1.92M | -$1.91M | -$1.53M | -$5.25M | -$1.66M | -$8.43M |
| EBITDA | -$1.74M | -$1.55M | -$1.94M | -$1.60M | -$1.57M | -$1.82M | -$1.93M | -$8.38M |
| EPS (basic) | -9.35 | -0.21 | -0.30 | — | -5.93 | -1.03 | -0.33 | — |
| EPS (diluted) | -9.35 | -0.21 | -0.30 | — | -5.93 | -1.03 | -0.33 | — |
| Weighted avg. shares (diluted) | 950,612 | 6.41M | 6.41M | — | 362,388 | 5.09M | 5.09M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $1.94M | $761,000 | $2.40M | $4.00M | $5.43M | $6.53M | $6.92M | $7.28M |
| Current assets | $2.12M | $1.14M | $2.81M | $4.08M | $5.65M | $7.27M | $7.55M | $8.03M |
| PP&E, net | — | — | $138,000 | $138,000 | $156,000 | $158,000 | $450,000 | $468,000 |
| Intangibles | $2.26M | $2.26M | $2.26M | $2.26M | $2.26M | $2.26M | $2.26M | $2.26M |
| Total assets | $4.38M | $3.41M | $5.87M | $7.21M | $9.70M | $11.42M | $12.04M | $12.64M |
| Current liabilities | $1.19M | $1.35M | $2.13M | $1.46M | $1.50M | $1.78M | $2.25M | $2.67M |
| Total liabilities | $1.45M | $1.61M | $2.85M | $2.38M | $3.23M | $3.75M | $5.76M | $5.05M |
| Shareholders' equity | $2.93M | $1.80M | $3.02M | $4.83M | $6.46M | $7.67M | $6.27M | $7.59M |
| Shares outstanding | 1.10M | 6.41M | 6.41M | 427,079 | 5.90M | 5.09M | 5.09M | 5.09M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.61M | -$1.84M | -$1.60M | -$1.51M | -$1.47M | -$2.02M | -$2.01M | -$3.51M |
| Investing cash flow | — | — | — | $15,000 | — | — | — | $500,000 |
| Financing cash flow | $2.79M | — | — | $58,000 | $64,000 | $1.62M | $1.65M | -$1,000 |
| Depreciation & amortization | $0 | $0 | $0 | $3,000 | $2,000 | $12,000 | $18,000 | $90,000 |
| Stock-based compensation | $100,000 | $104,000 | $113,000 | $217,000 | $253,000 | $238,000 | $315,000 | $244,000 |
Free plan shows the latest 8 periods; Pro shows all 55 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.